Evidence map›Paper›PMID 27039910›Full record

ArticleZeitschrift fur Rheumatologie2014

[Prophylaxis and treatment of infections in elderly patients with rheumatism].

C Kneitz, A Strangfeld, K Krüger

Abstract read
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

C KneitzKlinik f. Innere Medizin II, Klinikum Südstadt Rostock, Südring 81, 18059, Rostock, Deutschland. christian.kneitz@kliniksued-rostock.de.
A StrangfeldDeutsches Rheumaforschungszentrum, Berlin, Deutschland.
K KrügerPraxiszentrum, München, Deutschland.
German Rheumatism Research Centre · DEKlinikum Südstadt Rostock · DEOrthopädische Praxis · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In general, the risk of serious infections increases with age, mainly explained by immunosenescence and accumulation of comorbidities. Those patients with rheumatoid arthritis who are of advanced age and require treatment with immunosuppressive agents are at particular risk to develop an infectious disease. Actual requirement and kind of treatment on the one hand, and risk of infection on the other hand, have to be considered carefully for each patient. For example, in high-risk patients, it is important to use glucocorticoids in a minimal way, i.e. in low doses and as short as possible. Vaccination, especially against influenza and pneumococci, plays an essential role in preventing infectious diseases, particularly in the elderly. Nevertheless, in cases of suspected bacterial infection, empiric antibiotic therapy should be started promptly. Due to the burden of drugs taken by patients of advanced age, the benefits and possible side effects as well as potential drug interactions have to be carefully considered. In summary, drug treatment of the elderly requires bearing in mind the complete health status of the individual patient.

Indexed as

AgedAged, 80 and overAnti-Infective AgentsAntirheumatic AgentsArthritis, RheumatoidCommunicable DiseasesDose-Response Relationship, DrugFemaleGeriatric AssessmentHumansImmunosuppressive AgentsMaleRisk AssessmentAnti-Infective AgentsAntirheumatic AgentsImmunosuppressive AgentsElderlyRheumatoid arthritisRisk of infectionTreatmentVaccination

Identifiers

PMID27039910
OpenAlexW69496890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.